3P Biopharmaceuticals and Intervacc complete manufacturing agreement

3P Biopharmaceuticals and Intervacc complete manufacturing agreement for new vaccine against equine strangles

3P Biopharmaceuticals and the Swedish company Intervacc have now completed negotiations and signed the agreement for contract manufacturing of Strangvac. The agreement means that the production and documentation of the important validation batches required for registration of the new recombinant vaccine against equine strangles have been secured.

Jan-Ingmar Flock, CEO of Intervacc, says that ‘This is an important milestone in the process to complete the registration of Strangvac and especially considering that there is a huge need for a safe and efficacious vaccine against equine strangles as evidenced by all current reported outbreaks around the world’.

3P Biopharmaceuticals is an strategic partner to Intervacc and this manufacturing agreement fulfills the intentions from previously announced letter of intent and agreements for the first milestones. The agreement now signed by the companies covers transfer of the manufacturing technology, production of validation batches and long term future commercial manufacturing.

Strangvac is Intervacc´s vaccine against strangles, caused by Streptococcus equi in the horse. Strangles is a very contagious and severe infection leading to significant suffering and economic loss for the global equine industry. The vaccine is the first candidate in the pipeline of a new generation of vaccines based on recombinant proteins in Intervacc’s developmental program.